Introduction
The viral oncogenes human papillomavirus (HPV) 16 E6/E7 and SV40 large T antigen (Tag) are wellestablished promoters of tumorigenesis in humans and animal models. These viral oncoproteins inhibit Rb and p53 tumor suppressor genes as their primary mechanism of tumorigenesis. In contrast to the potent effects of the E6/7 oncogenes carried in the high-risk HPV genotypes such as HPV16, the low/intermediate-risk HPV virus subtypes carry variants of the E6 and E7 oncogenes that are not able to fully inhibit Rb and p53, rather only partially attenuating their tumor suppressor functions, although they are also able to trigger cervical carcinoma after a long latency period (Sang and Barbosa 1992; Giannoudis and Herrington, 2000) .
The RIP-Tag2 mouse model of multistage islet cell carcinogenesis shows an intriguing latency in the initiation of aberrant proliferation: although SV40 T antigen expression begins during embryonic development (day E8.5) (Hanahan, 1985) , focal hyperproliferation is not evident until 4 or 5 weeks of age. During this dichotomous period of oncogene expression with proliferative latency, the development, morphological appearance and functional characteristics of the islets of transgenic animals are indistinguishable from wild-type littermates. However, beginning at 4-5 weeks of age, hyperproliferation is activated in a subset of the oncogene-expressing islets, transforming them into lesions describable as hyperplasias and dysplasias (Hanahan, 1985) . The existence of this proliferative latency raises questions about the sufficiency of Tag for the full functional inactivation of the Rb proliferation and/or the p53 antiapoptotic signals, suggestive of possible similarity to the low/intermediate-risk subclasses of HPV viral oncogenes in cervical carcinogenesis.
Previous studies have assessed SV40 large T antigen's (Tag's) actions in abrogating p53 tumor suppressor function by crossing RIP-Tag2 mice to p53-null mice. The characteristic rates of apoptosis in the distinctive stages of the tumorigenesis pathway were unaltered in the RIP-Tag2;p53 À/À mice, indicating that Tag was suppressing p53's proapoptotic actions. Nevertheless, and counterintuitively, tumor size was reduced, as was the characteristic rate of tumor cell proliferation (Herzig et al., 1999) . These effects were attributed to the mutual stabilization of T antigen and p53 proteins by their interaction, which resulted in lower levels of the Tag oncoprotein in the p53 null animals (Herzig et al., 1999) . To date, analogous functional assessments of the necessity and sufficiency of Rb inactivation by the Tag oncogene in this model had not been performed, and it has remained to be established whether Tag is fully inhibiting the Rb proliferation pathway.
Here, we describe a surprising residual capability of the Rb pathway to regulate proliferation in the Tagexpressing RIP-Tag2 tumor model, as revealed by genetically abrogating two key regulators of this pathway, namely the CDK inhibitor p27 or Rb itself. The data indicate that attenuation rather than complete abrogation of Rb tumor suppressor gene function, in the context of fully inactivated p53, is sufficient to enable tumorigenesis in this model of islet cell tumors.
Results
Heterogeneous expression of the Tag oncoprotein suggests its incomplete pro-oncogenic function during the stages of tumor development.
Tag protein can be detected by immunostaining of pancreatic tissue sections from RIP-Tag2 mice. By both standard fluorescence and confocal microscopy techniques, it is readily apparent that the levels of Tag oncoprotein per cell are heterogeneous in each of the characteristic stages of tumorigenesis, namely histologically normal islets in young mice, and hyperplastic/ dysplastic islets and tumors in older mice (Hager et al., 2004 and Figure 1 ). This heterogeneity raises the question of whether variable Tag levels are a determinant in the progression to tumors. To address this possibility, we analyzed the expression levels of p53 in islets and tumors by immunohistochemistry and found that the heterogeneity of Tag protein levels seemed to partly correlate with the levels of p53 protein in the b cells (Figure 1 , top three panels), consistent with previous studies in this model (Efrat et al., 1987) . This result is also consistent with other studies that have shown Tag binding to p53 both inhibits p53 function while increasing abundance of p53 protein by limiting its MDM2-dependent degradation (Pipas and Levine, 2001; Saenz-Robles et al., 2001) . In addition, Tag protein levels vary similarly with the PCNA and Ki67 proliferation markers as revealed by immunofluorescence ( Figure 1 , three bottom panels and data not shown), suggesting that a threshold level of the T antigen oncoprotein may be deterministic for the state of b-cell hyperproliferation.
These considerations led us to hypothesize that the Rb tumor suppressor function might not be completely inactivated by the Tag oncoprotein, particularly in the or Rb itself.
The absence of p27 enhances islet cell tumorigenesis
The CDK inhibitor p27 is a key regulator of the Rb pathway that acts by suppressing both CDK4-and CDK2-associated hyperphosphorylation of Rb that functionally inactivates the Rb protein. p27 has been implicated as a tumor suppressor gene in a variety of human cancers and reduction or complete loss of p27 protein has been described in human tumors and shown to correlate with poor patient prognosis (Peters et al., 2004) .
To address the possible functional involvement of p27 in islet tumorigenesis, we crossed RIP-Tag2 mice to mice carrying a null ('KO') allele of p27 and assessed both tumor number and collective tumor volume (tumor burden) in mice that were heterozygous or homozygous null for p27 (Figure 2 ). There was a modest but not statistically significant increase in tumor burden comparing RIP-Tag2;p27
þ / þ to RIP-Tag2;p27 KO/ þ mice. Interestingly, RIP-Tag2;p27 KO/KO mice had a statistically significant increase in tumor burden compared both to RIP-Tag2;p27 þ / þ and to RIP-Tag2;p27 KO/ þ mice, suggesting that p27 was normally attenuating tumorigenesis. The mean tumor number was similar in all three p27 genotypes (Figure 2 ), indicating that the larger tumor burden in the RIP-Tag2;p27 KO/KO mice is the result of more expansive growth of a subset of the tumors that form, and is not due to an increased frequency in the conversion/progression of angiogenic progenitors into solid tumors. The increase in tumor size in RIP-Tag2;p27 KO/KO was accompanied by a two-fold increase in the proliferation rate compared to RIPTag2;p27 þ / þ mice; there was no change in the apoptosis rate ( Figure 3) . Moreover, grading of tumors from the RIP-Tag2;p27 KO/KO genotype compared to wild-type littermates indicated there was no change in malignant progression to an invasive phenotype in the absence of p27 gene (data not shown). Taken together, these data indicate that p27 protein continues to negatively regulate the cell cycle in tumor cells that are thought to be functionally Rb 'null' by virtue of the fact that they express the large T-antigen oncoprotein, which supports the proposition that Tag is not completely abrogating Rb protein function. This realization prompted further genetic experiments to address the possibility that residual Rb function in the face of Tag expression was limiting tumorigenesis.
Engineering a b-cell-specific Rb knockout
We next engineered a b-cell-specific Rb knockout (b-Rb 2002). Cre expression in the b-cells of the islets of Langerhans was achieved using a mouse line, RIP2-Cre, which specifically expresses the Cre recombinase under the rat insulin promoter (Gannon et al., 2000) .
We first evaluated the b-Rb KO/wt heterozygous and b-Rb KO homozygous animals in the absence of the RIP-Tag2 transgene. The b-Rb KO mice had a slightly increased body mass compared to age-matched Rb þ littermate controls, and showed a mild alteration in glucose metabolism, as evidenced by slower clearance of a bolus injection of glucose in a standard glucose tolerance test (data not shown). Histologically, the islets from heterozygous and homozygous b-Rb-targeted animals had a normal appearance throughout the Figure 2 Tumor burden for end-stage RIP-Tag2 animals in a p27 wild-type, heterozygous-knockout or homozygous-null background. Average tumor burden from a minimum of eight end-stage animals (13.5 weeks of age) is shown for each genotype studied. Numbers inside the bars indicate the average number of tumors observed per animal for each genotype at end-stage. Statistical significance was detemined by the Wilcoxon's test comparing wild-type versus p27 For proliferation rates, the Wilcoxon's test was used to determine statistical significance between wild-type versus p27
002). No statistical significance was observed in apoptosis rates
Incomplete inhibition of the Rb pathway in tumorigenesis O Casanovas et al lifespan of these animals. There was, however, evident pathological consequences in another organ: the homozygous null b-Rb KO animals required euthanasia at 18-20 weeks of age due to acute cachexia from the effects of Rb-null pituitary tumors that developed with 100% penetrance, apparently resultant to the 'leaky' expression of the RIP2-Cre transgene in the pituitary (Gannon et al., 2000; and M Hebrok, personal communication) . The pituitary has proved in other studies to be highly susceptible to tumorigenesis in the context of loss of Rb, as shown by the fact that Rb germline knockout heterozygote mice also develop pituitary tumors (Jacks et al., 1992) and by the high incidence of pituitary tumors in familial retinoblastoma mutations, clinically called trilateral retinoblastoma (Bader et al., 1980; Brownstein et al., 1984) . Since RIP-Tag2 mice develop pancreatic islet tumors by 12 weeks of age, the slower pituitary tumorigenesis did not preclude the analysis of the faster-growing islet tumors, and so RIP-Tag2; b-Rb KO mice were generated, and the pancreatic islet tumor pathway evaluated.
Abrogation of Rb accelerates islet cell tumorigenesis
RIP-Tag2;RIP2-Cre;Rb fl/fl mice showed a marked acceleration of tumor development compared to control RIP-Tag2;Rb fl/fl littermates. They had a 3 weeks shorter lifespan, with incipient death and obligatory euthanasia occurring at 11 weeks of age due to severe hypoglycemia and pancreatic tumor burden, the typical phenotype of islet cell tumors. At end-stage, both tumor number and tumor burden per animal were substantively increased in the knockouts compared to littermate control animals, with a five-fold greater number of tumors and a five-fold greater tumor burden in the Rb knockouts (Figure 4) .
Tumors from the RIP-Tag2;b-Rb KO animals were genotyped by PCR, revealing the expected homozygous deletion of the exon 19 with complete penetrance (data not shown). Moreover, we assessed Rb transcription by RT-PCR and found that the Rb mRNA was not present in any of the RIP-Tag2;b-Rb KO tumors analysed (data not shown). This result is consistent with previously published data from the Berns laboratory showing that the exon 19-excised Rb allele was unable to produce a stable mRNA (Marino et al., 2000; Ferguson et al., 2002) . Together, these data demonstrate that the tumors arising in the RIP-Tag2;b-Rb KO animals are indeed Rb null. Histologically, most of the Rb-null pancreatic islet tumors were similar to those from RIP-Tag2;Rb fl/fl controls, although some tumors appeared less red and hemorrhagic. These less frequent 'white' tumors were still highly vascularized, with characteristically dilated vessels, but were devoid of the blood islands that produce the red appearance typical of tumors in this model (Hashizume et al., 2000) .
To assess the basis for the early formation and increased size and number of tumors, proliferation and apoptosis rates were compared in stage-matched RIPTag2;b-Rb KO and littermate RIP-Tag2 controls. At end stage, the proliferation rates were increased by 37% in the knockouts compared to controls, while apoptotic rates were similar in both groups (Figure 5 ), indicating that the absence of Rb promotes increased tumor cell proliferation that is not accompanied by an altered frequency of apoptosis. We infer that apoptotic resistance conferred by survival signals such as IGF-2 expression (Christofori et al., 1994) and by inhibition of p53 by the Tag oncoprotein obviate any proapoptotic effects of Rb-loss.
In addition to increasing tumor cell proliferation rates and the number and growth rates of the solid tumors, the absence of Rb increased the prevalence of invasive carcinomas. There are three distinctive tumor stages in the RIP-Tag2 tumorigenesis pathway, as detailed in Lopez and Hanahan (2002) : encapsulated tumors with well-defined margins (islet tumors, IT), microinvasive carcinomas (invasive carcinoma type 1, IC1) and the relatively rare highly invasive carcinomas (invasive carcinoma type 2, IC2). As shown in Figure 6 , there is a significant increase in the percentage of tumors that fall into the more malignant categories IC1 and IC2 when comparing to encapsulated islet tumors (IT). This effect is more readily apparent in the more frequent IT and IC1 category, and less apparent in the IC2 category possibly due to the comparatively low frequency of the IC2 lesions, or the hypothesized different pathways of origin for the IC1 and IC2 tumors (Lopez and Hanahan 2002) . This shift to a more invasive phenotype in the absence of a functional Rb gene, together with the increased proliferation, tumor number and tumor burden in these animals, constitutes a significantly more malignant phenotype of these Rb-null tumors compared to those where Rb is wild type. 
Rb loss obviates the proliferative latency
We next analyzed the premalignant phase of islet tumorigenesis, asking whether the absence of Rb affected the proliferative latency seen in the first weeks of life and the frequency and characteristics of hyperplastic/dysplastic islet progenitor lesions that appear beginning at 4-6 weeks of age. Analysis of cell proliferation in 5-week-old animals, by tissue immunostaining subsequent to BrdU incorporation into S phase cells, indicated that virtually all (97%) of the islets in RIP-Tag2;b-Rb KO animals had switched to a hyperproliferative phenotype, as defined by the presence of multiple BrdU-positive cells in an islet, compared to 53% in control RIP-Tag2 animals (statistically significant by Wilcoxon's test, Po0.001). Moreover, the proliferation rate in each islet, determined by percent of BrdU-positive cells per total number of cells in each islet, was 3.3-fold higher in RIP-Tag2;b-Rb KO animals compared to control RIP-Tag2 littermates (Figure 7) . Thus, the absence of Rb in the b cells obviates the Collectively, the data demonstrate that Rb function is not completely inhibited by T antigen in the RIP-Tag2 mouse model, in that its genetic ablation results in accelerated pancreatic islet tumorigenesis. The constitutive absence of Rb in the islet b cells broadly affects all the stages of the T antigen-driven pathway, increasing both the incidence and growth rates of premalignant lesions, as well as the frequency of their progression to solid tumors. Subsequent to solid tumor formation, the absence of Rb increased tumor growth rates and the prevalence of invasive carcinomas.
Discussion
The Rb pathway is under multiple levels of both positive and negative control, and a number of genes that function in the latter context of repressing cell cycle progression are bona fide tumor suppressor genes, in that they are functionally abrogated in tumors, resulting in a deregulation of the cell cycle. In particular, Rb and p27
Kip1 are two important tumor suppressor genes whose function is frequently lost in human cancers. In our studies in the RIP-Tag2 mouse model of pancreatic islet cancer, the existence of a proliferative latency, in which hyperproliferation lags Tag expression, implicated a rate-limiting step to initiate the aberrant proliferation. Moreover, genomic CGH analysis revealed that broad regions of Chr. 14 and Chr. 6 that include Rb and p27, respectively, were recurrently lost in RIP-Tag2 tumor progression (Hodgson et al., 2001 ). These observations, together with our recent findings (Hager et al., 2004) that Tag expression is heterogeneous among the population of b cells populating all lesional stages in this pathway, suggested that Tag might not be fully inhibiting the tumor suppressor activity of Rb. Indeed, in this study, we have shown that genetic ablation of the p27 Kip1 or Rb genes accentuates tumorigenesis induced by the Tag oncogene, with loss of Rb in particular having wide-ranging effects on the parameters of this multistage tumorigenesis pathway.
Differential effects of p27 and Rb
The gene knockout crosses demonstrated that in this pathway p27 is a weak tumor suppressor. The timing of tumor formation and the number of solid tumors that arise were not significantly affected by heterozygous or homozygous loss of p27; only tumor size was modestly increased. In marked contrast, the RIP-Tag2;b-Rb KO animals showed an acceleration of the entire pathway, with all stages appearing earlier and at higher frequency; in particular, there was a consistent increase in both tumor number and tumor size. One explanation for this difference is that other CDK inhibitors (e.g. p57
Kip2
, p15, p16) continue to modulate Rb activity in the absence of p27, since it is evident from the b-Rb KO animals that partial Rb activity continues to interfere with tumor formation and growth.
Is Rb the effector component of the proliferative switch from phenotypic latency?
Our results clearly indicate that the Rb pathway is not completely inactivated by T-antigen in the RIPTag2 model, suggesting that either a stochiometric imbalance exists between Tag and Rb protein levels or that Tag is somehow incapable of fully inhibiting Rb function. Based on the extensive studies into the capability of Tag to inhibit Rb function both in cell culture and in in vivo animal models (Pipas and Levine, 2001), we favor the former hypothesis. Thus, our results suggest that a threshold level of T antigen may be necessary to induce particular b cells to initiate hyperproliferation and sustain it in the course of the tumorigenesis pathway. Since we detect heterogeneity in the levels of Tag protein at all stages and observe effects of genetic ablation of Rb on all stages, we infer there is no clonal outgrowth of high level Tagexpressing cells. This heterogeneity may relate to several factors: first, the chromosomal position into which the RIP-Tag transgene is integrated (on Chromosome 2; KM Smith and D Hanahan, unpublished results); second, the fact that proliferating b cells have been shown to downmodulate insulin gene transcription (Weir et al., 2001) and similarly may decrease insulin promoter-driven Tag expression; and third, the possibility of cell-to-cell variations in glucose sensitivity and levels of endogenous insulin II gene expression (Pipeleers 1992) , which may similarly affect the insulin II promoter-driven transgene.
In the period of proliferative latency where Tag is expressed without consequence, Rb function is arguably intact, given that none of the 400 islets have switched on aberrant hyperproliferation. Then, the proliferative switch is activated in sporadic islets beginning at 4-5 weeks of age. We infer that the switch involves attenuation of Rb function, since in the b-Rb KO mice most islets are hyperproliferative. Part of this sporadic attenuation of Rb function appears to involve variably higher levels of Tag expression, exceeding a threshold necessary for sufficient inhibition of Rb function. In addition, other regulators of Rb may be at play in modulating the residual Rb not inactivated by Tag, including members of the inhibitor family that governs CDK-mediated phosphorylation of Rb. Interestingly, loss of p27 did increase the proliferation rate of the solid tumors, inferring that it was indeed affecting the residual Rb not completely inactivated by Tag in this later stage. Given this observation, one can imagine that other Rb regulators are also involved in modulating residual Rb activity in the early phases of this tumorigenesis pathway. In addition, the initial proliferative switch that initiates this pathway to islet carcinomas involves the focal activation of expression of IGF-2, which acts initially as a survival factor (Christofori et al., 1994) . Thus, we currently envision the hyperproliferative switch as bimodal, which in the off position involves both Rb suppressor function and the lack of IGF survival signaling, and in the on position attenuation of Rb and activation of IGF-2. The temporal and functional relationship between these two events remains to be elaborated.
Implications for human cancer
It is pertinent to ask how studies using this 'atypical' viral oncogene might reflect on mechanisms of human carcinogenesis. In a general sense, the notion of Rb thresholds holding in check proliferative signals that would otherwise instruct neoplastic progression could well play into many situations where latent oncogenic cells are 'initiated' by mutation or by paracrine proliferative signals in the microenvironment. In lieu of homozygous deletion of Rb in incipient neoplasias, the other means of suppressing Rb function (e.g. by mutation or repression of CDK inhibitors) may produce this attenuated condition, evoking continuing proliferative latency or perhaps slow proliferation, until Rb mutations or other inhibitors of Rb serve to more completely inactivate its function, allowing hyperproliferation and neoplastic progression.
A more specific analogy with our studies can be made with the HPVs, which evoke cervical carcinomas via multistage pathways, in part using virally encoded oncogenes that abrogate p53 and Rb function. Papillomaviral genetics presents a clear case for the notion that 'attenuation' of tumor suppressors can influence carcinogenesis: a subclass of cervical cancer is caused by low/intermediate-risk HPV strains, such as HPV-6, -11, -31, -33 and -35. These strains have been shown to carry E6/E7 oncogenes that are unable to fully inhibit p53 and Rb, but rather only partially attenuate their functions, in contrast to high-risk strains such as HPV-16 and -18 (Sang and Barbosa 1992; Giannoudis and Herrington, 2000) . Consistent with the incompleteness of their suppression, tumors arising from infection by these low/intermediate-risk HPV cancers develop mutations in the p53 tumor suppressor gene more frequently than in the high-risk HPV cancers (Lo et al., 1992; Nakagawa et al., 1999; Kim et al., 2001) , suggesting that attenuation instead of complete inhibition of this tumor suppressor gene selects for secondary genetic or epigenetic hits that enhance tumorigenesis. Thus, much as the Tag oncoprotein 'attenuates' Rb function and manifests an initial proliferative latency in developing mouse islet carcinomas, asymptomatic HPV infections may similarly become initiated to develop into cervical intraepithelial neoplasias and carcinomas after a period of proliferative latency.
Materials and methods

Transgenic mice breeding
The generation of RIP-Tag2 mice as a model of pancreatic islet cell carcinogenesis has been reported previously (Hanahan, 1985) . p27 knockout animals inbred into the C57-Bl/6J background were purchased from Jackson Laboratories (Bar Harbor, ME, USA). RIP2-Cre transgenic mice, kindly provided by Mark Magnuson (Vanderbilt University Medical Center, Nashville, TN, USA) (Gannon et al., 2000) , were previously backcrossed into the C57-Bl/6J background for more than 15 generations. Rb-floxed allele animals, kindly provided by Anton Berns (The Netherlands Cancer Institute, Amsterdam, The Netherlands) (Marino et al., 2000; Ferguson et al., 2002) , were backcrossed into the C57-Bl/6J background for eight generations, and then crossed with the RIP-Tag2 and the RIP2-Cre in a Rb fl/wt heterozygous background and then intercrossed to Rb fl/fl animals to obtain RIP-Tag2;RIP2-Cre;Rb fl/fl animals. All mice were maintained in accordance with the University of California, San Francisco (UCSF) institutional guidelines governing the care of laboratory mice.
Tissue preparation and immunohistochemistry
Mice were anesthetized with tribromoethanol (Sigma) and heart perfused with PBS and then 10% zinc-buffered formalin (Medical Chemical Corp.). Pancreata were removed and postfixed in 10% zinc-buffered formalin overnight and processed for paraffin embedding as described previously (Lopez and Hanahan, 2002) . For frozen sections, the pancreata were embedded with or without fixation in OCT (Sakura Finetek) and frozen on dry ice as described previously (Lopez and Hanahan, 2002) . The following antibodies for immunofluorescence and immunohistochemistry were used: rabbit anti-Tag (preparation in the Hanahan laboratory); mouse anti-p53 (554165, BD Pharmingen); and mouse anti-Ki67 (556003, BD Pharmingen). Respective secondary antibodies conjugated to fluorescein, rhodamine or biotin were used as described, and ABC elite (Vector) and Fast-DAB (Sigma) were used for immunohistochemistry. BrdU, TUNEL staining and H&E grading were performed as described previously (Inoue et al., 2002; Lopez and Hanahan 2002) . For BrdU and TUNEL quantification, a minimum of 10 graded lesions per mouse and five mice per group were counted. Statistical analysis was performed using the nonparametric Wilcoxon's test and P-values of less than 0.05 were considered statistically significant.
Determination of number of angiogenic islets and tumor burden
Tumor burden was determined as described previously (Bergers et al., 2003) . Briefly, tumors were microdissected from freshly excised pancreata, tumor dimensions were measured with a ruler, and tumor volume was calculated using the formula (volume ¼ width 2 Â length Â 0.52) to approximate the volume of a spheroid. Average tumor burden was calculated as the sum of the volumes of all tumors per mouse using a minimum of eight to 10 mice. Comparisons between groups were analysed by the Wilcoxon's statistical test and P-values of less than 0.05 were considered statistically significant.
